Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-001 in Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
NCT04414163Phase 2Active, not recruiting
- Sponsor
- ImmuneOncia Therapeutics, Inc.
- Start
- Oct 2020
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMC-001 in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by ImmuneOncia Therapeutics, Inc. Primary endpoint: Objective Response Rate at 1 year. Started Oct 2020; status: active, not recruiting.
02
Drugs
IMC-001
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT04414163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414163.